BNBX Overview

BNB Plus Corp., formerly Applied DNA Sciences, Inc., is a digital asset treasury (DAT) company that has adopted BNB, the native cryptocurrency of the Binance blockchain ecosystem, as its primary reserve asset. Its segments include digital asset treasury, therapeutic deoxyribonucleic acid (DNA) production services, DNA tagging and security products and services. Its digital asset treasury segment is engaged in managing digital assets. Its therapeutic DNA production services segment is engaged in nucleic-acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP and LineaIVT. Its DNA tagging and security products and services segment is engaged in the manufacture and detection of DNA for industrial supply chains and security services. Its subsidiary LineaRx, Inc., is engaged in commercializing nucleic acid production solutions for the biopharmaceutical and diagnostics markets.

Wall Street analysts forecast BNBX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNBX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BNB Plus Corp revenue for the last quarter amounts to 565.39K USD, decreased -35.03

BNB Plus Corp. EPS for the last quarter amounts to -3.90 USD, decreased -99.07

BNB Plus Corp (BNBX) has 26 emplpoyees as of April 17 2026.

Today BNBX has the market capitalization of 3.26M USD.